Accessibility Menu
RenovaCare logo

RenovaCare(OTC) RCAR

Market Cap$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1997)-100%
5 Year-100%
1 Year+0%
1 Month+0%
$0.00
+0.00%
+0.00Today
RenovaCare last closing stock price
MetricPriceDate
Last closeUSD 0.002026-08-31
RenovaCare stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-08-19
1 month+0%USD 0.002026-07-16
3 month+0%USD 0.002026-05-26
Year to date+0%USD 0.002025-12-30
1 year+0%USD 0.002025-08-12
3 year+0%USD 0.002023-09-01
5 year-100%USD 1.262021-09-01
Since inception-100%USD 0.521997-10-09

RenovaCare Financials at a Glance

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$4.41M

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

158.36 (High)

Price

$0.00

Volume

160

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

RCAR News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About RenovaCare

RenovaCare, Inc. is a development-stage biotechnology and medical device company focused on autologous cellular therapies for medical and aesthetic applications. The company is advancing innovative technologies, including the CellMist System and SkinGun, aimed at regenerating human skin cells.

Products and Services
  • CellMist System for cell isolation and regeneration
  • SkinGun for delivering regenerative cells to treatment areas
  • Strategic collaboration with StemCell Systems GmbH
Growth Outlook
  • Potential market expansion in regenerative medicine and aesthetics
  • Innovative technology could lead to significant competitive advantages
  • Strategic partnerships may enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -$400,439, showing ongoing investment in R&D
  • Cash and cash equivalents of $100,738 as of September 30, 2022
  • Trailing twelve months (TTM) cash flow from operations remains negative, indicating high investment levels
RenovaCare, Inc. is positioned in the biotechnology sector, focusing on innovative solutions for skin regeneration. The company's flagship products, the CellMist System and SkinGun, are designed to harness the potential of autologous cellular therapies, which could revolutionize treatment options in both medical and aesthetic fields. The growth outlook for RenovaCare is promising, with opportunities for market expansion and the potential for strategic partnerships to enhance its research and development efforts. Despite the challenges reflected in recent financial performance, including negative net income and cash flow from operations, the ongoing investment in research and development indicates a commitment to innovation and long-term growth. Investors may find RenovaCare's focus on cutting-edge biotechnology and its strategic collaborations noteworthy as the company navigates the complexities of the healthcare landscape.
AI Generated • Aug 31, 2026

Industry

Biotechnology

Sector

Health Care

Employees

5

CEO

Kaiyo Nedd, MD

Website

www.renovacareinc.com

Headquarters

Scottsdale, AZ 85260, US

RCAR Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-94.75%

Return on Capital

-227.54%

Return on Assets

-122.27%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

87.35M

Volume

160

Avg. Volume

111.578

Financials (TTM)

Gross Profit

-$2.78K

Operating Income

-$7.82M

EBITDA

-$6.52M

Operating Cash Flow

-$4.13M

Capital Expenditure

$0.00

Free Cash Flow

-$4.13M

Cash & ST Invst.

$100.74K

Total Debt

$800.00K

RenovaCare Performance Analysis

RenovaCare annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 0N/A
RenovaCare sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31N/A
Q12022-03-31N/A
Q22022-06-30N/A
Q32022-09-30N/A
RenovaCare annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -0.05N/A
RenovaCare sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-3120.6%
Q12022-03-31-28.6%
Q22022-06-30-39.4%
Q32022-09-30144.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2022YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$100.00Market cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$100.00

N/A

Employees

1

N/A

Net Income

$1.08M

+163.5%

EBITDA

-$398.39K

+76.3%

Quarterly Fundamentals

Name
Q3 2022YOY CHG

Total Cash

$100.74K

-97.1%

Total Debt

$800.00K

+1752.2%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$800.00K

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-1.22%

N/A

Return on Invested Capital

-2.30%

N/A

Free Cash Flow

-$148.22K

+83.9%

Operating Cash Flow

-$148.22K

+83.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PARDPoniard Pharmaceuticals, Inc.
$0.00+0.00%
LOWLFLowell Farms Inc.
$0.00+0.00%
ASFXAmerican Scientific Resources, Incorporated
$0.00+0.00%
MDITMedite Cancer Diagnostics, Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.15-0.12%
NVDANvidia
$230.36+0.01%
PATHUiPath
$15.19-0.17%
INTCIntel
$95.80+0.05%

Questions About RCAR

What is the current price of RenovaCare?

RenovaCare is trading at $0.00 per share.

What is the 52-week range for RenovaCare?

Over the past 52 weeks, RenovaCare has traded between $0.00 and $0.00.

How much debt does RenovaCare have?

As of the most recent reporting period, RenovaCare reported total debt of $30.50K.

How much cash does RenovaCare have on hand?

RenovaCare reported $2.85M in cash and cash equivalents in its most recent financial results.

What is RenovaCare’s dividend yield?

RenovaCare does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services